Emre ASILTÜRK, Melahat ÇOBAN, Süleyman DOLU, Bekir EROL, Hamit Yaşar ELLİDAĞ, Yıldız KILAR SÖZER

The association of urotensin II with arterial stiffness and atherosclerosis in patients with autosomal dominant polycystic kidney disease

Aim: Cardiovascular events are associated with increased mortality in patients with autosomal dominant polycystic kidney disease(ADPKD). Urotensin II (UT II) is the most potent vasoconstrictor peptide. The aim of the study was to investigate the relationshipbetween UT II and arterial stiffness (AS) and atherosclerosis in ADPKD patients.Material and Methods: This cross-sectional study was conducted on 55 ADPKD patients with a mean age of 50 ± 14.4years. Thepresence of AS was determined with brachial-ankle pulse wave velocity (baPWV) and the presence of atherosclerosis was determinedwith carotid artery intima-media thickness (CA-IMT). Plasma UT II levels were determined by enzyme-linked immunosorbent assay.Results: Mean log10 UT II was 0.92±0.16 ng/mL. Mean baPWV and CA-IMT were 7.65±1.5 m/sec and 0.63±0.13 mm, respectively.Log10 UT II (p=0.009), baPWV (p < 0.001) and CA-IMT (p=0.001) were high in patients compared to healthy individuals. There was anindependent relationship between log10 UT II and creatinine (p=0.044) and spot urine protein-creatinine ratio (UPCR) (p=0.026) inmultiple regression analysis. There was no relationship between log10 UT II and baPWV and CA-IMT.Conclusion: High plasma UT II levels were observed in ADPKD patients compared to healthy individuals. There was a relationshipbetween UT II and kidney dysfunction and proteinuria. There was no relationship between UT II and AS and atherosclerosis.

PDF

___

1. Kocaman O, Oflaz H, Yekeler E, et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004;43:854-60.
2. Wang D, Iversen J, Wilcox CS, et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003;64:1381–8.
3. Townsend RR, Wimmer NJ, Chirinos JA, et al. Aortic PWV in chronic kidney disease. A CRIC ancillary study. Am J Hypertens 2010;23:282–9.
4. Borresen ML, Wang D, Strandgaard S. Pulse wave reflection is amplified in normotensive patients with autosomaldominant polycystic kidney disease and normal renal function. Am J Nephrol 2007;27:240-6.
5. Kocyigit I, Kaya MG, Orscelik O, et al. Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients. Am J Nephrol 2012;36:11-8.
6. Richards AM, Charles C. Urotensin ΙΙ in the cardiovascular system. Peptides 2004;25:1795-802.
7. Wilkinson IB, Affolter JT, de Haas SL, et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002;53:341-7.
8. Tsoukas P, Kane E, Giaid A. Potential clinical implications of the urotensin II receptor antagonists. Front Pharmacol 2011;2:38.
9. Song N, Ding W, Chu S, et al. Urotensin II stimulates vascular endothelial growth factor secretion from adventitial fibroblasts in synergy with angiotensin II. Circ J 2012;76:1267-73.
10. Satıroglu O, Durakoglugil ME, Cetin M, et al. The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow. Interv Med Appl Sci 2016;8:158–63.
11. Totsune K, Takahashi K, Arihara Z, et al. Role of urotensin II in patients on dialysis. Lancet 2001;358:810-1.9.
12. Mallamaci F, Cutrupi S, Pizzini P, et al. Urotensin II in endstage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol 2005;18:727–32.
13. Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001;19:2185–90.
14. Mori N, Hirose T, Nakayama T, et al. Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure. Peptides 2009;30:400-8.
15. Ravani P, Tripepi G, Pecchini P, et al. Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. Kidney Int 2008;73:95-101.
16. Ashton N. Renal and vascular actions of urotensin II. Kidney Int 2006;70:624-9.
17. Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994;343:824-7.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
20. Homma S, Hirose N, Ishida H, et al. Carotid plaque and intimamedia thickness assessed by B-mode ultrasonography in subjects ranging from young adults to centenarians. Stroke 2001;32:830-5.
21. Yokoyama H, Shoji T, Kimoto E, et al. Pulse wave velocity in lower-limb arteries among diabetic patients with peripheral arterial disease. J Atheroscler Thromb 2003;10:253-8.
22. Garoufi A, Drapanioti S, Marmarinos A, et al. Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study. BMC Nephrol 2017;18:113.
23. Böhm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002;135:25-7.
24. Zoccali C, Mallamaci F. Urotensin ΙΙ: a cardiovascular and renal update. Current Opinion in Nephrology and Hypertension 2008;17:199-204.
25. Zhang AY, Chen YF, Zhang DX, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol 2003;285:792–8.
26. Song W, Abdel-Razik AE, Lu W, et al. Urotensin II and renal function in the rat. Kidney Int 2006;69:1360-8.
27 Abdel-Razik AE, Forty EJ, Balment RJ, et al. Renal haemodynamic and tubular actions of urotensin II in the rat. J Endocrinol 2008;198:617–24.
28. Tian L, Li C, Qi J, et al. Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction. Am J Physiol Endocrinol Metab 2008;295:E1234-42.
29. Mosenkis A, Kallem RR, Danoff TM, et al. Renal impairment, hypertension and plasma urotensin II. Nephrol Dial Transplant 2011;26:609-14.
30. Balat A, Pakir IH, Gok F, et al. Urotensin-II levels in children with minimal change nephrotic syndrome. Pediatr Nephrol 2005;20:42-5.
31. Balat A, Karakok M, Yılmaz K, et al. UrotensinII immunoreactivity in children with chronic glomerulonephritis. Renal Failure 2007;29:573–8.
32. Zhang YG, Li J, Li YG, et al. Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta. J Hypertens 2008;26:1119–26.
33. Hassan GS, Douglas SA, Ohlstein EH, et al. Expression of urotensin-II in human coronary atherosclerosis. Peptides 2005;26:2464-72.
34. Suguro T, Watanebe T, Ban Y, et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007;20:211–7.
35. Bousette N, Patel L, Douglas SA, et al. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004;176:117-23.
36. Zoccali C, Mallamaci F, Tripepi G, et al. Urotensin II is an inverse predictor of incident cardiovascular events in endstage renal disease. Kidney Int 2006;69:1253-8.
37. Stefoni S, Cianciolo G, Donati G, et al. Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002;61:324-35.
38. Hillier C, Berry C, Petrie MC, et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 2001;103:1378-81.
39. Affolter JT, Newby DE, Wilkinson IB, et al. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002;54:617-21.
40. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol 2002;137:579–588.
41. Watanabe T, Kanome T, Miyazaki A. Relationship between hypertension and atherosclerosis: from a viewpoint of the most potent vasoconstrictor human urotensin II. Curr Hypertens Rev 2006;2:237–46.
42. Mallamaci F, Cutrupi S, Pizzini P, et al. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 2006;19:505-10.
43. Daugherty A, Rateri DL. T lymphocytes in atherosclerosis: the yin-yang of Th1 and th2 influence on lesion formation. Circ Res 2002;90:1039–40.
44. Aiyar N, Guida B, Ao Z, et al. Differential levels of “urotensinII-like” activity determined by radio-receptor and radioimmuno-assays. Peptides 2004;25:1339-47.